ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,309.34
0.02%
Dow Jones
39,820.66
0.03%
US Dollar vs MXN
16.6089
0.32%
Brent Oil
82.485
-1.25%
Bitcoin
69,751.79
-2.38%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Aptinyx Inc (APTX)

  7. Aptinyx Inc (APTX) Noticias

APTX

Aptinyx (APTX)

Aptinyx Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:APTX
FechaHoraFuenteTítuloSímboloCompañía
21/12/202309:52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTXAptinyx Inc
27/06/202313:14Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:APTXAptinyx Inc
24/05/202315:50Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:APTXAptinyx Inc
24/05/202315:44Edgar (US Regulatory)Withdrawal of Registration Statement (rw)NASDAQ:APTXAptinyx Inc
23/05/202307:26Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:APTXAptinyx Inc
15/05/202315:46Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:APTXAptinyx Inc
11/05/202307:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:APTXAptinyx Inc
28/04/202315:19Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:APTXAptinyx Inc
30/03/202315:31Edgar (US Regulatory)Annual Report (10-k)NASDAQ:APTXAptinyx Inc
30/03/202315:05Business WireAptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic AlternativesNASDAQ:APTXAptinyx Inc
27/02/202315:03Business WireAptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate UpdateNASDAQ:APTXAptinyx Inc
31/01/202306:47Business WireAptinyx to Present at the SVB Securities Global Biopharma ConferenceNASDAQ:APTXAptinyx Inc
05/01/202315:18Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:APTXAptinyx Inc
12/12/202205:25TipRanksH.C. Wainwright Keeps Their Buy Rating on Aptinyx (APTX)NASDAQ:APTXAptinyx Inc
10/11/202206:45Business WirePreclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for NeuroscienceNASDAQ:APTXAptinyx Inc
09/11/202222:26TipRanksSVB Securities Keeps Their Buy Rating on Aptinyx (APTX)NASDAQ:APTXAptinyx Inc
09/11/202209:16TipRanksBMO Capital Remains a Buy on Aptinyx (APTX)NASDAQ:APTXAptinyx Inc
08/11/202215:32Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:APTXAptinyx Inc
08/11/202215:05Business WireAptinyx Reports Third Quarter 2022 Financial Results and Recent HighlightsNASDAQ:APTXAptinyx Inc
03/11/202206:30Business WireClinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH GrantNASDAQ:APTXAptinyx Inc
18/10/202206:45Business WireAptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022NASDAQ:APTXAptinyx Inc
25/08/202206:30Business WireAptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy BodiesNASDAQ:APTXAptinyx Inc
12/08/202206:15Business WireAptinyx Reports Results from Phase 2b Study of NYX-2925 in FibromyalgiaNASDAQ:APTXAptinyx Inc
05/08/202207:38TipRanksBMO Capital Sticks to Its Buy Rating for Aptinyx (APTX)NASDAQ:APTXAptinyx Inc
04/08/202215:05Business WireAptinyx Reports Second Quarter 2022 Financial Results and Recent HighlightsNASDAQ:APTXAptinyx Inc
02/08/202221:35TipRanksSVB Securities Maintains a Buy Rating on Aptinyx (APTX)NASDAQ:APTXAptinyx Inc
15/07/202206:47Business WireAptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022NASDAQ:APTXAptinyx Inc
24/06/202213:33Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:APTXAptinyx Inc
22/06/202206:47Business WireAptinyx to Participate in H.C. Wainwright 1st Annual Mental Health ConferenceNASDAQ:APTXAptinyx Inc
23/05/202205:29TipRanksH.C. Wainwright Thinks Aptinyx’s Stock is Going to RecoverNASDAQ:APTXAptinyx Inc
 Showing the most relevant articles for your search:NASDAQ:APTX

Su Consulta Reciente

AMEX
SPY
SPDR S&P 500
NYSE
KO
Coca Cola
NASDAQ
GOOGL
Alphabet
NASDAQ
AMZN
Amazon.com
NASDAQ
MSFT
Microsoft
NYSE
NKE
Nike
USOTC
ADDYY
Adidas (QX)
NYSE
AXP
American Express
COIN
BTCUSD
Bitcoin
CCOM
SILVER
SILVER
CCOM
US500
US 500
NASDAQ
NVDA
NVIDIA
COIN
ETHUSD
Ethereum
NYSE
MRK
Merck
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados